Cargando…

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age

Background. Protecting young children from pandemic influenza should also reduce transmission to susceptible adults, including pregnant women. Methods. An open study assessed immunogenicity and reactogenicity of a heterologous booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03(B) (AS03(B) is an Adjuv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nolan, Terry, Izurieta, Patricia, Lee, Bee-Wah, Chan, Poh Chong, Marshall, Helen, Booy, Robert, Drame, Mamadou, Vaughn, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224137/ https://www.ncbi.nlm.nih.gov/pubmed/24973461 http://dx.doi.org/10.1093/infdis/jiu359

Ejemplares similares

AS03(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial
por: Kosalaraksa, Pope, et al.
Publicado: (2015)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
por: Gillard, Paul, et al.
Publicado: (2014)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
por: Nolan, Terry, et al.
Publicado: (2014)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03(A)-Adjuvanted Vaccination in Adults
por: Lasko, Benjamin, et al.
Publicado: (2011)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant
por: Li, Man, et al.
Publicado: (2013)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
por: Ramirez-Valdez, Ramiro A., et al.
Publicado: (2023)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice
por: Aitken, Amelia S., et al.
Publicado: (2018)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa
por: Oboh, Mary Aigbiremo, et al.
Publicado: (2022)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gdp64dq9em95hnr12982u9uasi